In short. The mechanism claimed for each feature, and the point at which the mechanism and the clinical result come apart in practice.
Key points
- Explaining how a feature is thought to work is not the same as showing that it produces a different result for a person.
- The mechanism is where the reasoning starts, and a study comparing outcomes is where it has to finish.
- Where the study does not exist, the mechanism is being asked to carry the claim alone.
Surface and gel are the two features most often described in mechanistic terms, and the mechanism is usually explained correctly. The gap opens later, between what the mechanism does and what it is said to mean for a result.
The claimed mechanism for surface
Any implant forms a capsule of tissue around it, and that capsule can tighten, producing firmness, distortion and discomfort. Texturing is intended to disrupt the orderly formation of that capsule so that contraction happens less readily. It is a reasonable idea and it has some support. What it does not have is a settled answer, because studies report different results, use different definitions of the outcome, and follow people for different lengths of time. The claim sits where the disagreement is.
The claimed mechanism for gel
The gel inside a shell can be more or less cohesive. Cohesion changes the behaviour of the material if the shell is disrupted: it holds together rather than spreading into surrounding tissue. That is a material property and it is well described. What follows from it is a change in how a rupture presents and how readily it is picked up on imaging. What does not follow is a reduction in rupture, and the labelling for cohesive devices continues to state a rupture risk.
A mechanism is not an outcome
Explaining how a feature is thought to work is not the same as showing that it produces a different result for a person. The mechanism is where the reasoning starts, and a study comparing outcomes is where it has to finish. Where the study does not exist, the mechanism is being asked to carry the claim alone.
Where the two features interact
A device is a shell and a fill together. A surface cannot be chosen independently of the gel inside it, and the combination has one profile rather than a set of separable benefits. A brochure that lists features as though each could be selected on its own is describing a catalogue rather than a device, and a person reading it may come away thinking they have chosen something they have not.
The claim that surface addresses the lymphoma association
It does not. The association attaches to rougher surfaces rather than being removed by them, which is why several regulators have restricted those surfaces. A feature that was introduced to address one problem and became associated with another is the clearest example in this subject of why a mechanism description cannot be read as a safety statement.
Three things to separate
- The mechanism — how the feature is thought to work.
- The outcome — whether a result is measurably different over a meaningful period.
- The association — anything the feature has been linked to, whether or not it explains it.
Keeping those three apart is what makes a mechanistic explanation useful instead of persuasive.
Frequently asked questions
How is a textured surface supposed to work?
By disrupting the orderly formation of the capsule that forms around any implant, so that the tissue does not contract evenly around it. The mechanism is plausible and the studies disagree about how much it achieves, which is why the claim remains limited rather than established.
What does gel cohesion change?
It changes what happens after the shell is disrupted. A cohesive gel holds together; a less cohesive one runs. That affects how a rupture presents and how it is detected, and it does not affect whether the shell is disrupted in the first place.
Are surface and gel independent choices?
Not entirely. A device combines a shell and a fill, so a surface cannot be selected separately from the gel inside it. That matters when a brochure treats each feature as a benefit that can be chosen individually rather than as one combination with one overall profile.
Risks & Limitations
- No generation of implant is a lifetime device, and a proportion will need removal or replacement at some point.
- Rougher surfaces carry an established association with a rare lymphoma of the tissue around the implant.
- Rupture can occur without symptoms, so surveillance over time is advised whatever device is in place.
- Capsular contracture is a recognised risk and no surface has eliminated it.
- A design feature is a modification with a reason behind it, not a demonstrated improvement in outcome.
When to Seek Care
- A change in the shape or size of a breast, or a new lump — have it assessed by a clinician.
- Swelling that comes and goes, or a fluid collection around an implant.
- Persistent pain or firmness around an implant, or a new and persistent symptom.
- Contact the service that holds your records, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved breast implant labelling and safety communications
- European Medicines Agency (EMA) and national regulators — breast implant assessment reports and restrictions
- National Medical Products Administration (NMPA, China) — approved devices and their indications
- World Health Organization (WHO) — classification of tumours of the breast, including implant-associated lymphoma
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.